TMPRSS2 and cancer: SLC45A3:ERG (S:E) fusion is found in approximately 6% of ERG fusion prostate cancer, and concurrent TMPRSS2 and SLC45A3 fusions to ERG are found in 11% of ERG fusion-positive cancer [8].